Sign In
Buy NRIX
$15.48
-0.89 (-5.44%)
At Close: Jun 03, 2026
Wall Street Analysts Believe Nurix Therapeutics, Inc. (NRIX) Could Rally 195.93%: Here's is How to Trade
11:36am, Monday, 24'th Jul 2023
The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 195.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates
06:37pm, Thursday, 13'th Jul 2023
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.01 per share a year ago.
Does Nurix Therapeutics, Inc. (NRIX) Have the Potential to Rally 192.09% as Wall Street Analysts Expect?
10:57am, Wednesday, 24'th May 2023
The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 192.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
04:01pm, Tuesday, 09'th May 2023
SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patie
Wall Street Analysts Predict a 233.33% Upside in Nurix Therapeutics, Inc. (NRIX): Here's What You Should Know
11:26am, Thursday, 04'th May 2023
The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 233.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
How Much Upside is Left in Nurix Therapeutics, Inc. (NRIX)? Wall Street Analysts Think 134.94%
11:26am, Tuesday, 18'th Apr 2023
The consensus price target hints at a 134.9% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
07:00pm, Thursday, 13'th Apr 2023
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.95 per share a year ago.
Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead
11:28am, Tuesday, 21'st Mar 2023
Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.
Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength?
05:23am, Tuesday, 21'st Mar 2023
Nurix Therapeutics, Inc. (NRIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre
Nurix's stock rallies on Gilead's option
09:00am, Monday, 20'th Mar 2023
Shares of Nurix Therapeutics Inc. NRIX, -0.99% gained about 6% in premarket trading on Monday after Gilead Sciences Inc. GILD, -3.18% said it exercised the option to exclusively license Nurix's target
Nurix: Promising Early Data From This Protein Degrader Company
11:39pm, Sunday, 19'th Mar 2023
NRIX announced early data at ASH last year. The company has a couple of major partnerships.
Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
04:01pm, Monday, 06'th Mar 2023
SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
06:50pm, Thursday, 09'th Feb 2023
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -27.94% and 65.46%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the
Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
07:01am, Wednesday, 04'th Jan 2023
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pati
After Plunging -15.8% in 4 Weeks, Here's Why the Trend Might Reverse for Nurix Therapeutics, Inc. (NRIX)
10:51am, Wednesday, 28'th Dec 2022
Nurix Therapeutics, Inc. (NRIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analy
